5th International Mycoplasma qPCR Testing User Day
PharmaLab Pre-Conference Event on 25 November 2024
Background & Objectives
Mycoplasma contamination of biopharmaceutical products (also known as biologics or large molecules) resulting from cell culture contamination in the manufacturing process poses a potential health risk to patients. Mycoplasmas can affect virtually every cell culture parameter with often only minor visible effects, creating an uncontrollable environment that is undesirable in the pharmaceutical industry. Therefore, regulatory agencies require manufacturers to test their biopharmaceutical products and to ensure the absence of mycoplasmas in released products. Most regulatory agencies have issued guidelines that provide protocols for mycoplasma testing, and some give recommendations for the validation of rapid NAT (nucleic acid amplification techniques) testing methods. This satellite symposium will give you a scientifically sound introduction into the field of Rapid Mycoplasma testing with a specific focus on NAT and more specifically on qPCR methods. It includes talks, case studies as well as interactive round table discussions from users to users.
The Pre-Conference Workshop is directed to responsible personnel involved in Quality Control testing of biopharmaceuticals and biologics, e.g.:
- QC Managers
- Microbiologists and Process Microbiologists
- Analytical Experts
- Biosafety and Pathogen Safety SME’s
- Responsible Authority Employers
It is also useful for service providers, such as contract research organisations and contract manufacturers.
Become part of the PharmaLab Congress 2024 – as a Speaker
Please complete our online form. The deadline for submissions is 30 April 2024